These reports suggested the usefulness of anti-PD1 Abs for PD-L1-expressing non-melanoma skin cancers, and a phase II clinical trial of nivolumab for the treatment of non-melanoma epithelial skin malignancies is ongoing (jRCT: 2031190048) [3]. The gene discussed is CD274; the disease is skin neoplasm.